ARTICLE | Product Development
BGI, Quidel launch COVID-19 diagnostics while HHS funds Mesa’s point-of-care test
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 19, 2020 12:47 AM UTC
Updated on Mar 25, 2020 at 9:46 PM UTC
Industry is continuing to ramp up COVID-19 testing capacity to meet demand, as two diagnostics enter the U.S. market and HHS’s BARDA grants its fourth award for a COVID-19 assay.
BGI Genomics Co. Ltd. (SZSE:300676) launched its real-time fluorescent reverse transcriptase PCR (RT-PCR) COVID-19 diagnostic in the U.S. while it awaits an emergency use authorization (EUA) from FDA in the near future. To alleviate the shortage of COVID-19 diagnostics, FDA on Monday began to allow distribution and use of tests while manufacturers prepared EUA requests (see “FDA Expanding U.S. COVID-19 Test Capacity”)...